Discussion
Among people with hereditary angioedema (HAE), the one-time gene-editing therapy lonvoguran ziclumeran — simply called lonvo-z — significantly reduces the frequency of swelling attacks, minimizes the need for on-demand treatment, and improves quality of life. These are the newest findings from a global Phase 3 clinical trial, dubbed…